Macular Degeneration Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Macular Degeneration stocks.

Macular Degeneration Stocks Recent News

Date Stock Title
May 7 APLS Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
May 7 APLS Apellis Pharmaceuticals (APLS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
May 7 GILD Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
May 7 APLS Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates
May 7 APLS Apellis Pharmaceuticals GAAP EPS of -$0.54 misses by $0.09, revenue of $172.3M beats by $8.04M
May 7 APLS Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
May 6 EYPT EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)
May 6 APLS Apellis Pharmaceuticals Q1 2024 Earnings Preview
May 6 EYPT EyePoint tumbles 30% premarket on failed Phase 2 study
May 6 EYPT Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?
May 6 EYPT EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy
May 6 APLS Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
May 4 GILD 23 Most Profitable Stocks of the Last 12 Months
May 3 GILD Forbes Has Listed Gilead as One of America’s Best Employers for Diversity
May 3 ADVM Adverum Biotechnologies to Participate in Upcoming May Investor Conferences
May 3 GILD The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
May 2 GILD Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
May 2 ADVM Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
May 1 ADVM Adverum Biotechnologies a new buy at H.C. Wainwright on wet AMD gene therapy
May 1 APLS Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for
Macular Degeneration

Macular degeneration, also known as age-related macular degeneration (AMD or ARMD), is a medical condition which may result in blurred or no vision in the center of the visual field. Early on there are often no symptoms. Over time, however, some people experience a gradual worsening of vision that may affect one or both eyes. While it does not result in complete blindness, loss of central vision can make it hard to recognize faces, drive, read, or perform other activities of daily life. Visual hallucinations may also occur but these do not represent a mental illness.Macular degeneration typically occurs in older people. Genetic factors and smoking also play a role. It is due to damage to the macula of the retina. Diagnosis is by a complete eye exam. The severity is divided into early, intermediate, and late types. The late type is additionally divided into "dry" and "wet" forms with the dry form making up 90% of cases.Preventive efforts include exercising, eating well, and not smoking. Antioxidant vitamins and minerals do not appear to be useful for prevention. There is no cure or treatment that returns vision already lost. In the wet form, anti-VEGF medication injected into the eye or less commonly laser coagulation or photodynamic therapy may slow worsening. Supplements in those who already have the disease may slow progression.In 2015 it affected 6.2 million people globally. In 2013 it was the fourth most common cause of blindness after cataracts, preterm birth, and glaucoma. It most commonly occurs in people over the age of fifty and in the United States is the most common cause of vision loss in this age group. About 0.4% of people between 50 and 60 have the disease, while it occurs in 0.7% of people 60 to 70, 2.3% of those 70 to 80, and nearly 12% of people over 80 years old.

Browse All Tags